Company intelligence / Profile preview
American CryoStem Corporation
- Ownership
- Private
- Development stage
- Other
Overview
American CryoStem has received FDA IND clearance for two Phase I clinical trials using its proprietary ATCELL™ autologous adipose-derived mesenchymal stem cell therapy—one targeting Post-Concussion Syndrome in retired military/athletes and another for Long COVID/PASC. The company’s technology enables the collection, processing, cryopreservation, expansion, and delivery of patient-specific stem cells for personalized regenerative treatments. No published efficacy results yet; current focus is on safety/tolerability assessment in early-phase studies[3][6][9].
- Therapeutic areas
- DermatologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Autologous mesenchymal stem cells (adipose-derived)Adipose tissue-based cellular therapies
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on American CryoStem Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on American CryoStem Corporation.